Teva inks commercialization deal for Eylea biosimilar

13 January 2025

Teva Pharmaceuticals (TASE: TEVA) has partnered with Klinge Biopharma and Formycon (FSE: FYB) to commercialize FYB203, a biosimilar to Eylea (aflibercept), in Europe and Israel.

The drug will be marketed as Ahzantive, pending regulatory approval, and targets retinal diseases such as neovascular age-related macular degeneration.

The collaboration, which combines Teva’s extensive European distribution network with Formycon’s biosimilar development expertise, builds on the firms' earlier success with Ranivisio (ranibizumab) commercialization in Europe.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biosimilars